Revenue Breakdown
Composition ()
No data
Revenue Streams
Haemonetics Corp (HAE) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Hospital, accounting for 44.5% of total sales, equivalent to $145.50M. Other significant revenue streams include Plasma and Blood Center. Understanding this composition is critical for investors evaluating how HAE navigates market cycles within the Medical Equipment, Supplies & Distribution industry.
Profitability & Margins
Evaluating the bottom line, Haemonetics Corp maintains a gross margin of 56.47%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 23.22%, while the net margin is 13.20%. These profitability ratios, combined with a Return on Equity (ROE) of 19.30%, provide a clear picture of how effectively HAE converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, HAE competes directly with industry leaders such as XRAY and VCYT. With a market capitalization of $2.97B, it holds a leading position in the sector. When comparing efficiency, HAE's gross margin of 56.47% stands against XRAY's 46.10% and VCYT's 72.07%. Such benchmarking helps identify whether Haemonetics Corp is trading at a premium or discount relative to its financial performance.
